EVALUATE THE CONCENTRATION OF SERUM CFDNA AND INTEGRITY AS A NON-INVASIVE MARKER TO DISTINGUISH BETWEEN MALIGNANT AND BENIGN BREAST LESION. RJDNMD 2024, 31 (1), 366-389.